Savara Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Savara Inc (SVRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $68.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-03-30
- Savara Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $68.00K, a 75.54% decline from fiscal 2019.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $278.00K, a 76.12% decline from fiscal 2018.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $1.16M, a 31.16% decline from fiscal 2017.
- Savara Inc effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was $1.69M, a 50.18% increase from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2020-12-31 | $68.00K 10-K · filed 2022-03-30 |
| 2019-12-31 | $278.00K 10-K · filed 2021-03-10 |
| 2018-12-31 | $1.16M 10-K · filed 2020-03-12 |
| 2017-12-31 | $1.69M 10-K · filed 2019-03-13 |
| 2016-12-31 | $1.13M 10-K · filed 2018-03-14 |
| 2015-12-31 | $674.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |